Innovative Approaches to Obtain Minors' Consent for Biomedical HIV Prevention Trials: Multi-Site Quasi-Experimental Study of Adolescent and Parent Perspectives

Amelia Knopf, Mary A Ott, Claire Burke Draucker, J Dennis Fortenberry, Daniel H Reirden, Renata Arrington-Sanders, John Schneider, Diane Straub, Rebecca Baker, Giorgos Bakoyannis, Gregory D Zimet, Amelia Knopf, Mary A Ott, Claire Burke Draucker, J Dennis Fortenberry, Daniel H Reirden, Renata Arrington-Sanders, John Schneider, Diane Straub, Rebecca Baker, Giorgos Bakoyannis, Gregory D Zimet

Abstract

Background: Despite the high burden of new HIV infections in minor adolescents, they are often excluded from biomedical HIV prevention trials, largely owing to the ethical complexities of obtaining consent for enrollment. Researchers and ethics regulators have a duty to protect adolescents-as a special category of human subjects, they must have protection that extends beyond those afforded to all human subjects. Typically, additional protection includes parental consent for enrollment. However, parental consent can present a risk of harm for minor adolescents. Research involving minor adolescents indicate that they are unwilling to join biomedical trials for stigmatized health problems, such as HIV, when parental consent is required. This presents a significant barrier to progress in adolescent HIV prevention by creating delays in research and the translation of new scientific evidence generated in biomedical trials in adult populations.

Objective: This protocol aims to examine how parental involvement in the consent process affects the acceptability of hypothetical participation in biomedical HIV prevention trials from the perspectives of minor adolescents and parents of minor adolescents.

Methods: In this protocol, we use a quasi-experimental design that involves a simulated consent process for 2 different HIV prevention trials. The first trial is modeled after an open-label study of the use of tenofovir disoproxil fumarate and emtricitabine as preexposure prophylaxis for HIV. The second trial is modeled after a phase IIa trial of an injectable HIV integrase inhibitor. There are 2 groups in the study-minor adolescents aged 14 to 17 years, inclusive, and parents of minor adolescents in the same age range. The adolescent participants are randomized to 1 of 3 consent conditions with varying degrees of parental involvement. After undergoing a simulated consent process, they rate their willingness to participate (WTP) in each of the 2 trials if offered the opportunity. The primary outcome is WTP, given the consent condition. Parents undergo a similar process but are asked to rate the acceptability of each of the 3 consent conditions. The primary outcome is acceptability of the consent method for enrollment. The secondary outcomes include the following: capacity to consent among both participant groups, the prevalence of medical mistrust, and the effects of the study phase (eg, phase IIa vs the open-label study) and drug administration route (eg, oral vs injection) on WTP (adolescents) and acceptability (parents) of the consent method.

Results: Enrollment began in April 2018 and ended mid-September 2019. Data are being analyzed and dissemination is expected in April 2020.

Conclusions: The study will provide the needed empirical data about minor adolescents' and parents' perspectives on consent methods for minors. The evidence generated can be used to guide investigators and ethics regulators in the design of consent processes for biomedical HIV prevention trials.

International registered report identifier (irrid): DERR1-10.2196/16509.

Keywords: HIV; adolescence; biomedical ethics; parental consent.

Conflict of interest statement

Conflicts of Interest: None declared.

©Amelia Knopf, Mary A Ott, Claire Burke Draucker, J Dennis Fortenberry, Daniel H Reirden, Renata Arrington-Sanders, John Schneider, Diane Straub, Rebecca Baker, Giorgos Bakoyannis, Gregory D Zimet. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 30.03.2020.

Figures

Figure 1
Figure 1
A sample qualitative data analysis matrix for adolescent participants. UBACC: University of California, San Diego Brief Assessment of Capacity to Consent.

References

    1. Centers for Disease Control and Prevention (CDC) 2018. [2020-01-28]. HIV and Youth
    1. Hess KL, Hu X, Lansky A, Mermin J, Hall HI. Lifetime risk of a diagnosis of HIV infection in the United States. Ann Epidemiol. 2017 Apr;27(4):238–43. doi: 10.1016/j.annepidem.2017.02.003.
    1. FDA-Approved Drugs. 2018. [2020-01-27]. TRUVADA_ (emtricitabine/tenofovir disoproxil fumarate) tablets .
    1. Spong CY, Bianchi DW. Improving public health requires inclusion of underrepresented populations in research. J Am Med Assoc. 2018 Jan 23;319(4):337–8. doi: 10.1001/jama.2017.19138.
    1. Pace JE, Siberry GK, Hazra R, Kapogiannis BG. Preexposure prophylaxis for adolescents and young adults at risk for HIV infection: is an ounce of prevention worth a pound of cure? Clin Infect Dis. 2013 Apr;56(8):1149–55. doi: 10.1093/cid/cis1020.
    1. Hoffman LF, Francis NK, Catallozzi M, Francis JKR, Stanberry LR, Rosenthal SL. Inclusion of adolescents in clinical trials for sexually transmitted infections: a review of existing registered studies. J Adolesc Health. 2016 May;58(5):576–8. doi: 10.1016/j.jadohealth.2016.01.007.
    1. MacQueen KM, Karim QA. Practice brief: adolescents and HIV clinical trials: ethics, culture, and context. J Assoc Nurses AIDS Care. 2007;18(2):78–82. doi: 10.1016/j.jana.2007.01.002.
    1. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research . NIH VideoCast. Washington, DC: Department of Health, Education, and Welfare; 1977. [2020-01-27]. Research Involving Children: Report and Recommendations .
    1. Department of Health & Human Services FDA-Approved Drugs. 2019. [2020-01-30]. Sec. 50.55 Requirements for Permission by Parents or Guardians and for Assent by Children .
    1. Department of Health and Human Services eCFR — Code of Federal Regulations. 2018. [2020-01-30]. Title 45: Public Welfare. Part 46 - Protection of Human Subjects .
    1. Brody JL, Annett RD, Scherer DG, Perryman ML, Cofrin KM. Comparisons of adolescent and parent willingness to participate in minimal and above-minimal risk pediatric asthma research protocols. J Adolesc Health. 2005 Sep;37(3):229–35. doi: 10.1016/j.jadohealth.2004.09.026.
    1. Brody JL, Scherer DG, Annett RD, Turner C, Dalen J. Family and physician influence on asthma research participation decisions for adolescents: the effects of adolescent gender and research risk. Pediatrics. 2006 Aug;118(2):e356–62. doi: 10.1542/peds.2005-2589.
    1. Catallozzi M, de Roche AM, Hu M, Breitkopf CR, Chang J, Ipp LS, Francis JKR, Rosenthal SL. Adolescent and parent willingness to participate in Microbicide safety studies. J Pediatr Adolesc Gynecol. 2017 Mar;30(1):82–7. doi: 10.1016/j.jpag.2016.06.009.
    1. Francis JK, Fraiz LD, de Roche AM, Catallozzi M, Breitkopf CR, Rosenthal SL. Management of adolescent-parent Dyads' discordance for willingness to participate in a reproductive health clinical trial. J Empir Res Hum Res Ethics. 2018 Feb;13(1):42–9. doi: 10.1177/1556264617745409.
    1. Wallace M, Middelkoop K, Smith P, Pike C, Bennie T, Chandia J, Churchyard G, Gray G, Latka MH, Mathebula M, Nchabeleng M, Roux S, Slack C, Strode A, Bekker L. Feasibility and acceptability of conducting HIV vaccine trials in adolescents in South Africa: going beyond willingness to participate towards implementation. S Afr Med J. 2018 Mar 28;108(4):291–8. doi: 10.7196/SAMJ.2017.v108i4.12909.
    1. Reed JL, Huppert JS. Predictors of adolescent participation in sexually transmitted infection research: brief report. J Adolesc Health. 2008 Aug;43(2):195–7. doi: 10.1016/j.jadohealth.2008.01.020.
    1. Rojas NL, Sherrit L, Harris S, Knight JR. The role of parental consent in adolescent substance use research. J Adolesc Health. 2008 Mar;42(2):192–7. doi: 10.1016/j.jadohealth.2007.07.011.
    1. Fisher CB, Arbeit MR, Dumont MS, Macapagal K, Mustanski B. Self-consent for HIV prevention research involving sexual and gender minority youth: reducing barriers through evidence-based ethics. J Empir Res Hum Res Ethics. 2016 Feb;11(1):3–14. doi: 10.1177/1556264616633963.
    1. Knopf AS, Ott MA, Liu N, Kapogiannis BG, Zimet GD, Fortenberry JD, Hosek SG. Minors' and young adults' experiences of the research consent process in a Phase II safety study of pre-exposure prophylaxis for HIV. J Adolesc Health. 2017 Dec;61(6):747–54. doi: 10.1016/j.jadohealth.2017.06.013.
    1. Macapagal K, Coventry R, Arbeit MR, Fisher CB, Mustanski B. 'I Won't Out Myself Just to Do a Survey': sexual and gender minority adolescents' perspectives on the risks and benefits of sex research. Arch Sex Behav. 2017 Jul;46(5):1393–409. doi: 10.1007/s10508-016-0784-5.
    1. Hein IM, Troost PW, Lindeboom R, Benninga MA, Zwaan CM, van Goudoever JB, Lindauer RJ. Accuracy of the MacArthur competence assessment tool for clinical research (MacCAT-CR) for measuring children's competence to consent to clinical research. JAMA Pediatr. 2014 Dec;168(12):1147–53. doi: 10.1001/jamapediatrics.2014.1694.
    1. Nelson LR, Stupiansky NW, Ott MA. The influence of age, health literacy, and affluence on adolescents' capacity to consent to research. J Empir Res Hum Res Ethics. 2016 Apr;11(2):115–21. doi: 10.1177/1556264616636232.
    1. Hume M, Lewis LL, Nelson RM. Meeting the goal of concurrent adolescent and adult licensure of HIV prevention and treatment strategies. J Med Ethics. 2017 Dec;43(12):857–60. doi: 10.1136/medethics-2016-103600.
    1. Gilbert AL, Knopf AS, Fortenberry JD, Hosek SG, Kapogiannis BG, Zimet GD. Adolescent self-consent for biomedical human immunodeficiency virus prevention research. J Adolesc Health. 2015 Jul;57(1):113–9. doi: 10.1016/j.jadohealth.2015.03.017.
    1. Knopf AS, Gilbert AL, Zimet GD, Kapogiannis BG, Hosek SG, Fortenberry JD, Ott MA, Adolescent Medicine Trials Network for HIV/AIDS Interventions Moral conflict and competing duties in the initiation of a biomedical HIV prevention trial with minor adolescents. AJOB Empir Bioeth. 2017;8(3):145–52. doi: 10.1080/23294515.2016.1251506.
    1. Smedley BD, Stith AY, Nelson AR, editors. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: National Academies Press; 2003.
    1. Elopre L, McDavid C, Brown A, Shurbaji S, Mugavero MJ, Turan JM. Perceptions of HIV pre-exposure prophylaxis among young, black men who have sex with men. AIDS Patient Care STDS. 2018 Dec;32(12):511–8. doi: 10.1089/apc.2018.0121.
    1. Cahill S, Taylor SW, Elsesser SA, Mena L, Hickson D, Mayer KH. Stigma, medical mistrust, and perceived racism may affect PrEP awareness and uptake in black compared to white gay and bisexual men in Jackson, Mississippi and Boston, Massachusetts. AIDS Care. 2017 Nov;29(11):1351–8. doi: 10.1080/09540121.2017.1300633.
    1. Mustanski B, Macapagal K, Thomann M, Feinstein BA, Newcomb ME, Motley D, Fisher CB. Parents' perspectives about adolescent boys' involvement in biomedical HIV prevention research. Arch Sex Behav. 2018 Oct;47(7):1923–35. doi: 10.1007/s10508-017-1035-0.
    1. Nelson KM, Carey MP, Fisher CB. Is guardian permission a barrier to online sexual health research among adolescent males interested in sex with males? J Sex Res. 2019;56(4-5):593–603. doi: 10.1080/00224499.2018.1481920.
    1. Mustanski B, Coventry R, Macapagal K, Arbeit MR, Fisher CB. Sexual and gender minority adolescents' views on HIV research participation and parental permission: a mixed-methods study. Perspect Sex Reprod Health. 2017 Jun;49(2):111–21. doi: 10.1363/psrh.12027.
    1. Jeste DV, Palmer BW, Appelbaum PS, Golshan S, Glorioso D, Dunn LB, Kim K, Meeks T, Kraemer HC. A new brief instrument for assessing decisional capacity for clinical research. Arch Gen Psychiatry. 2007 Aug;64(8):966–74. doi: 10.1001/archpsyc.64.8.966.
    1. McCumber M, Cain D, LeGrand S, Mayer KH, Murphy DA, Psioda MA, Seña AC, Starks TJ, Hudgens M. Adolescent medicine trials network for HIV/AIDS interventions data harmonization: rationale and development of guidelines. JMIR Res Protoc. 2018 Dec 21;7(12):e11207. doi: 10.2196/11207.
    1. Torsheim T, Cavallo F, Levin KA, Schnohr C, Mazur J, Niclasen B, Currie C, FAS Development Study Group Psychometric validation of the revised family affluence scale: a latent variable approach. Child Indic Res. 2016;9:771–84. doi: 10.1007/s12187-015-9339-x.
    1. Hartley JE, Levin K, Currie C. A new version of the HBSC Family Affluence Scale - FAS III: Scottish Qualitative Findings from the International FAS Development Study. Child Indic Res. 2016;9:233–45. doi: 10.1007/s12187-015-9325-3.
    1. Zimet GD, Dahlem NW, Zimet SG, Farley GK. The multidimensional scale of perceived social support. J Pers Assess. 1988;52(1):30–41. doi: 10.1207/s15327752jpa5201_2.
    1. Kerr M, Stattin H. What parents know, how they know it, and several forms of adolescent adjustment: further support for a reinterpretation of monitoring. Dev Psychol. 2000 May;36(3):366–80.
    1. Thompson Hayley S, Valdimarsdottir Heiddis B, Winkel Gary, Jandorf Lina, Redd William. The Group-Based Medical Mistrust Scale: psychometric properties and association with breast cancer screening. Prev Med. 2004 Feb;38(2):209–18. doi: 10.1016/j.ypmed.2003.09.041.
    1. Widman L, Choukas-Bradley S, Helms SW, Golin CE, Prinstein MJ. Sexual communication between early adolescents and their dating partners, parents, and best friends. J Sex Res. 2014;51(7):731–41. doi: 10.1080/00224499.2013.843148.
    1. Knopf A, Bakoyannis G, Zimet G. Urban American women's willingness to participate in HIV vaccine trials. the biannual meeting of the International AIDS Society; July 20, 2016; Durban, South Africa. 2016.
    1. Lally M, Goldsworthy R, Sarr M, Kahn J, Brown L, Peralta L, Zimet G. Evaluation of an intervention among adolescents to reduce preventive misconception in HIV vaccine clinical trials. J Adolesc Health. 2014 Aug;55(2):254–9. doi: 10.1016/j.jadohealth.2014.01.006.
    1. Zheng B. Summarizing the goodness of fit of generalized linear models for longitudinal data. Stat Med. 2000 May 30;19(10):1265–75. doi: 10.1002/(sici)1097-0258(20000530)19:10<1265::aid-sim486>;2-u.
    1. Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika. 1976;63(3):655–60. doi: 10.2307/2335748.
    1. Bauer P. Multiple testing in clinical trials. Stat Med. 1991 Jun;10(6):871–89; discussion 889. doi: 10.1002/sim.4780100609.
    1. Wang N, Robins JM. Large-sample theory for parametric multiple imputation procedures. Biometrika. 1998;85(4):935–48. doi: 10.1093/biomet/85.4.935.
    1. Robins JM, Wang NS. Inference for imputation estimators. Biometrika. 2000;87(1):113–24. doi: 10.1093/biomet/87.1.113.
    1. Meng XL. Multiple-imputation inferences with uncongenial sources of input. Statist Sci. 1994;9(4):538–58. doi: 10.1214/ss/1177010269.
    1. Lu KF, Tsiatis AA. Multiple imputation methods for estimating regression coefficients in the competing risks model with missing cause of failure. Biometrics. 2001 Dec;57(4):1191–7. doi: 10.1111/j.0006-341x.2001.01191.x.
    1. Bakoyannis G, Zhang Y, Yiannoutsos CT. Nonparametric inference for Markov processes with missing absorbing state. Stat Sin. 2019 Oct;29(4):2083–104. doi: 10.5705/ss.202017.0175.
    1. Sandelowski M. Whatever happened to qualitative description? Res Nurs Health. 2000 Aug;23(4):334–40. doi: 10.1002/1098-240x(200008)23:4<334::aid-nur9>;2-g.
    1. Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005 Nov;15(9):1277–88. doi: 10.1177/1049732305276687.
    1. Miles MB, Huberman AM, Saldaña J. Qualitative Data Analysis: A Methods Sourcebook. Third edition. Thousand Oaks, CA: Sage Publications Inc; 2014.
    1. Nelson RM, Lewis LL, Struble K, Wood SF. Ethical and regulatory considerations for the inclusion of adolescents in HIV biomedical prevention research. J Acquir Immune Defic Syndr. 2010 Jul;54(Suppl 1):S18–24. doi: 10.1097/QAI.0b013e3181e2012e.
    1. Ott MA. Vulnerability in HIV prevention research with adolescents, reconsidered. J Adolesc Health. 2014 Jun;54(6):629–30. doi: 10.1016/j.jadohealth.2014.03.014.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel